EDAP Announces Third Quarter 2023 Financial Results
- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -
- - Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -
- Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology -
- Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT -
LYON, France, November 9, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023. - The decrease was driven by 1 Focal One system sold in the third quarter 2023 versus 3 systems sold in the third quarter of 2022.
- Operating loss for the third quarter of 2023 was EUR 5.6 million (USD 6.0 million), compared to an operating loss of EUR 2.1 million (USD 2.2 million) in the third quarter of 2022.
- A conference call and webcast to discuss the third quarter 2023 financial results will be hosted Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary, today, Thursday, November 9th, 2023, at 8:30am EDT.